Saldarriaga, Clara and Atar, Dan and Stebbins, Amanda and Lewis, Basil S. and Abidin, Imran Zainal and Blaustein, Robert O. and Butler, Javed and Ezekowitz, Justin A. and Hernandez, Adrian F. and Lam, Carolyn S. P. and O'Connor, Christopher M. and Pieske, Burkert and Ponikowski, Piotr and Roessig, Lothar and Voors, Adriaan A. and Anstrom, Kevin J. and Armstrong, Paul W. and Grp, VICTORIA Study (2022) Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction. European Journal of Heart Failure, 24 (5). pp. 782-790. ISSN 1388-9842, DOI https://doi.org/10.1002/ejhf.2468.
Full text not available from this repository.Abstract
Aims Coronary artery disease (CAD) portends worse outcomes in heart failure (HF). We aimed to characterize patients with CAD and worsening HF with reduced ejection fraction (HFrEF) and evaluate post hoc whether vericiguat treatment effect varied according to CAD. Methods and results Cox proportional hazards were generated for the primary endpoint of cardiovascular death or HF hospitalization (CVD/HFH). CAD was defined as previous myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting. Of 5048 patients in VICTORIA with available data on CAD status, 2704 had CAD and were older, were more frequently male, diabetic, and had a lower glomerular filtration rate than those without CAD (all p <0.0001). Use of implantable cardioverter defibrillators and cardiac resynchronization therapy (CRT) was higher in patients with versus without CAD (33.5% vs. 21.1%; p p = 0.0006). The primary endpoint of CVD/HFH was higher in those with versus without CAD (40.6 vs. 30.1/100 patient-years; adjusted hazard ratio HR] 1.23; p <0.001) as was all-cause mortality (17.9% vs. 12.7%; adjusted HR 1.32; p <0.001). The primary outcome of CVD/HFH associated with vericiguat in patients with or without CAD was 38.8 versus 27.6 per 100 patient-years and for placebo was 42.6 versus 32.7 per 100 patient-years (interaction p = 0.78). Conclusion In this post hoc study, CAD was associated with more CVD and HFH in patients with HFrEF and worsening HF. Vericiguat was beneficial and safe regardless of concomitant CAD.
| Item Type: | Article |
|---|---|
| Funders: | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, Bayer AG, Wuppertal, Germany |
| Uncontrolled Keywords: | Heart failure; Coronary artery disease; Comorbidity; Vericiguat; Cardiovascular death; Heart failure hospitalization |
| Subjects: | R Medicine R Medicine > RC Internal medicine |
| Divisions: | Faculty of Medicine |
| Depositing User: | Ms. Juhaida Abd Rahim |
| Date Deposited: | 19 Oct 2023 08:15 |
| Last Modified: | 20 Oct 2023 01:17 |
| URI: | http://eprints.um.edu.my/id/eprint/42029 |
Actions (login required)
 |
View Item |
